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Background:  Tryptase is a trypsin-like serine proteinase stored in the
cytoplasmic granules of mast cells, which has been implicated in a number of
mast cell related disorders such as asthma and rheumatoid arthritis. Unlike
almost all other serine proteinases, tryptase is fully active in plasma and in the
extracellular space, as there are no known natural inhibitors of tryptase in
humans. Leech-derived tryptase inhibitor (LDTI), a protein of 46 amino acids, is
the first molecule found to bind tightly to and specifically inhibit human tryptase
in the nanomolar range. LDTI also inhibits trypsin and chymotrypsin with similar
affinities. The structure of LDTI in complex with an inhibited proteinase could be
used as a template for the development of low molecular weight tryptase
inhibitors.
Results: The crystal structure of the complex between trypsin and LDTI was
solved at 2.0 Å resolution and a model of the LDTI–tryptase complex was
created, based on this X-ray structure. LDTI has a very similar fold to the third
domain of the turkey ovomucoid inhibitor. LDTI interacts with trypsin almost
exclusively through its binding loop (residues 3–10) and especially through the
sidechain of the specificity residue Lys8. Our modeling studies indicate that
these interactions are maintained in the LDTI–tryptase complex.
Conclusions: The insertion of nine residues after residue 174 in tryptase,
relative to trypsin and chymotrypsin, prevents inhibition by other trypsin
inhibitors and is certainly responsible for the higher specificity of tryptase
relative to trypsin. In LDTI, the disulfide bond between residues 4 and 25
causes a sharp turn from the binding loop towards the N terminus, holding the
N terminus away from the 174 loop of tryptase. 
Introduction
Tryptase (E.C. 3.4.21.59) is a trypsin-like serine pro-
teinase, stored in the cytoplasmic granules of mast cells
[1]. Like trypsin, it cleaves peptide substrates on the car-
boxyl side of lysine and arginine residues. Although it
shares high sequence homology with both trypsin and
chymotrypsin (~37% sequence identity), human tryptase
is unusual among the serine proteinases in that its func-
tional unit seems to be a tetramer of Mr 120 000. Upon
mast cell degranulation, tryptase is released along with
other mediators, such as histamine, chymase and proteo-
glycans into the extracellular space [2]. Human tryptase
can be measured readily in a variety of biological fluids
following mast cell activation. This enzyme has been
implicated in the pathogenesis of a variety of human 
diseases which are characterized by the recruitment of
large numbers of mast cells and their degranulation.
These include allergic and inflammatory disorders, such
as asthma, psoriasis, interstitial lung diseases, rheumatoid
arthritis, gingivitis and peridontitis [3]. Mast cell tryptase
has also been implicated in tumorgenesis and angiogene-
sis due to its potential to activate enzymes involved in
matrix degradation, for example prourokinase and the
matrix metalloproteinase prostromelysin [4,5]. Recently,
a tryptase-like enzyme activity has been detected in
several breast cancer cell lines [6]. Tryptase-like enzymes
have also been described as taking part in the activation
and internalization of pathogenic viruses such as influenza
virus, Sendai virus and human immunodeficiency virus
(HIV) [7,8].
In contrast to almost all other serine proteinases, tryptase
is fully active in plasma and in the extracellular space, as
there are no known natural inhibitors of tryptase in
humans [9]. None of the naturally occurring antipro-
teinases regulating the activity of other trypsin-like serine
proteinases (e.g. mucus-proteinase inhibitor, antithrom-
bin III, α1-proteinase inhibitor, α2-macroglobulin or C1-
esterase inhibitor) show activity towards tryptase [10,11].
Although tryptase is inhibited by the general synthetic
inhibitors of trypsin-like serine proteinases, such as diiso-
propyl fluorophosphate, phenylmethylsulfonyl fluoride and
tosyl-L-lysine chloromethane [9,12], these compounds are
unsuitable for in vivo and even for most in vitro applica-
tions due to their high toxicity and low stability. Further-
more, the only other inhibitors known to affect tryptase,
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the peptide-arginine aldehydes leupeptin and antipapain
[11] and benzamidine derivatives [13,14], are of limited
usefulness because they are nonspecific and inhibit tryptase
only in the micromolar range.
Leech-derived tryptase inhibitor (LDTI) is a protein of 46
amino acids, isolated from the European medicinal leech
Hirudo medicinalis, which has recently been expressed to
high yield in the yeast Saccharomyces cerevisiae [10,15].
LDTI shows 40% sequence homology with Kazal-type
inhibitors (ovomucoids), such as turkey ovomucoid third
domain and porcine pancreatic trypsin inhibitor, and has
the highest degree of sequence identity (45%) with the
nonclassical Kazal-type inhibitors bdellin B-3 and rhod-
niin, inhibitors isolated from the leech Hirudo medicinalis
and the insect Rhodnius prolixus, respectively (reviewed in
[16]). The three-dimensional structures of several Kazal-
type inhibitors are known [17] as well as the three-dimen-
sional structure of LDTI in solution, as determined by
two-dimensional NMR [18]. LDTI is the first protein
found to tightly bind and specifically inhibit human
tryptase in the nanomolar range (Ki = 1.4 nM [10]). LDTI
also inhibits trypsin and chymotrypsin with similar affini-
ties with Ki = 0.9 nM and 20 nM, respectively [10]. LDTI
does not inhibit any of the serine proteinases of the blood
coagulation cascade, implying that its biological function
might be to block defense mechanisms initiated by host
mast cell tryptase [10]. Two molecules of LDTI are suffi-
cient to inactivate the tryptase tetramer against protein
substrates, although small peptides are still cleaved at
50% activity [10]. The binding loop responsible for pro-
teinase inhibition was proposed to be Cys6 to Lys11, with
Lys8 as the primary determinant of inhibitor specificity
[10,18]. LDTI inhibits the tryptase-mediated proliferation
of human keratinocytes and fibroblasts and can also block
replication of HIV-1 virus [15,19]. Therefore, LDTI may
be a useful agent to evaluate the pathophysiological func-
tions of human tryptase and may exhibit therapeutic poten-
tial. The structure of LDTI in complex with one of the
inhibited proteinases would serve as a template for the
development of low molecular weight tryptase inhibitors.
In this paper the three-dimensional crystal structure of
LDTI in complex with porcine pancreatic trypsin (E.C.
3.4.21.4) at 2.03 Å resolution is described. In addition,
modeling studies of the LDTI–tryptase complex, based
on this crystal structure and a previously constructed
homology model of the unbound tryptase [20], have been
carried out and provide an explanation as to why LDTI
inhibits tryptase while other related inhibitors do not.
Results and discussion
Crystallization and crystal analysis
Two different crystals of LDTI in complex with porcine
trypsin were obtained. Crystals of form I had a maximum
size of 0.1 × 0.1 × 0.1 mm3 and were obtained after one
month at room temperature with 8% (w/v) polyethylene
glycol 8000 and 2% dioxane in 0.1 M Tris-HCl buffer,
pH 8.5. Crystals of form II were obtained in 30% (v/v)
2-propanol, 0.2 M ammonium acetate in 0.1 M Tris-HCl
buffer, pH 8.5 and grew to a maximum size of 0.4 × 0.3 ×
0.1 mm3 after 27 months at room temperature. Similar
attempts to cocrystallize LDTI with commercially obtained
bovine trypsin and bovine chymotrypsin were unsuccessful.
The crystal form I, which diffracts to 3 Å resolution,
belongs to the orthorhombic space group P212121 with unit
cell dimensions of a = 62.02 Å, b = 105.36 Å, c = 116.01 Å.
X-ray data were processed with an overall Rmerge of 14%,
96% completeness and a multiplicity of 3.7. The asym-
metric unit contains two trypsin–LDTI complexes.  Crystal
form II has unit cell parameters of a = b = 63.70 Å,
c = 130.86 Å and belongs to the tetragonal space group
P43212. Assuming one molecule of the LDTI–trypsin
complex in the asymmetric unit, the VM is 2.30 Å3/Da
protein. The structure was determined using X-ray data
from crystal form II due to the higher resolution of crystal
form II compared to crystal form I (2.03 Å versus 3.0 Å res-
olution), the higher symmetry space group and the pres-
ence of one trypsin–LDTI complex in the asymmetric
unit in the crystal form II (Table 1).
Structure solution/refinement
The rotation function using trypsin alone as the trial struc-
ture gave a single solution of 9.9 standard deviations above
the mean and was 2.5 times higher than the next highest
peak. After applying the indicated rotation of α = 81.5º,
β = 161.6º and γ = 74.0º, translation functions were calcu-
lated for the two enantiomorphic space groups P41212 and
P43212. In P41212, the highest peak was 6.9σ above the
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Table 1
Data processing statistics.
Space group P43212
a, b (Å) 63.70
c (Å) 130.86
Unit cell volume (Å3) 531 000
Asymmetric unit content 1 trypsin–LDTI complex
Vm (Å3/Da) 2.35
Resolution (Å) 2.03
Rmerge* overall (2.10–2.03 Å)(%)† 11.5 (43.8)
Number of measurements 150 264
Number of unique observations 17 213
Multiplicity overall (2.10–2.03 Å)† 8.7 (6.2)
Completeness overall (2.10–2.03 Å)(%)† 94.3 (79.4)
*Rmerge = ΣIi – < I > / Σ < I >, summed over all measured intensities
Ii. †Values in parentheses relate to the 2.10–2.03 Å resolution shell.
mean and 1.12 times higher than the next peak (correla-
tion coefficient 35.6%; R factor 50.6%), while in P43212
the highest peak was 15.6σ above the mean and 1.92 times
higher than the next highest peak (correlation coefficient
59.3%; R factor 42.1%), clearly implying that the latter
space group was the correct one. After applying the sug-
gested translation of ∆x = 0.8658, ∆y = 0.4474, ∆z = 0.0584,
rigid-body fitting with AMoRe brought the R factor down
to 41.7% while the correlation coefficient increased to
60.6%. Examination of the packing within the crystallo-
graphic unit cell indicated reasonable contacts between
trypsin molecules and no overlap of symmetry-related
molecules. Superposition of the human leukocyte elas-
tase–turkey ovomucoid inhibitor complex [21] (PDB acces-
sion code 1PPF) indicated adequate space for the LDTI
molecule in this packing arrangement.
Starting with the properly rotated and translated model of
trypsin, the structure was refined without molecular
dynamics. LDTI could gradually be built into the elec-
tron density, starting with the binding loop (residues
4–13) and part of the central α helix (residues 22–32).
After the next round of refinement, residues 14–21 and
33–40 could be added. Later refinement allowed the
placement of residues 2, 3 and 41. Solvent molecules
were added as they appeared in the Fo–Fc difference
electron-density map as long as they had hydrogen-
bonding potential and were not in areas where we
expected missing residues of LDTI to be located. Minor
corrections to trypsin included rejoining residues 60–61
and 145–146 (chymotrypsin numbering for trypsin is used
throughout), which were cleaved in the model of β-
trypsin used in molecular replacement, flipping peptides
26–27 and 147–148, repositioning the sidechain of Tyr217
(due to contacts with LDTI), minor sidechain corrections
to agree with the Swiss-Prot sequence (Asn155→Asp,
Gln186→Glu), and substitution of Asn115 with D-Asp
(detailed below).
All atoms for trypsin could be located. The electron
density N-terminal to residue 2 of LDTI ends abruptly,
implying that Lys1 may have been cleaved off by
trypsin. The electron density of Pro41 is very weak and
beyond this residue is not interpretable, implying that
the C terminus is disordered in the crystals as was also
seen in the solution structure determination [18]. A total
of 138 solvent molecules were also located during the
course of refinement (Table 2). The temperature factors
of LDTI are lowest in the binding loop (12–20 Å2 for the
Cα atoms of residues 6–10) and increase linearly (correla-
tion coefficient = +0.95) with distance from the Cα atom
of the catalytic Ser195 in trypsin (Figure 1). Examination
of the packing shows that LDTI is in very weak contact
with symmetry-related molecules and hence is held in
the crystalline array only by its attachment to trypsin.
Except for its binding loop, LDTI is free to move and
apparently does so, much like a basket loosely held by its
handle. A least-squares line through Figure 1 implies a
root mean square (rms) displacement of 3.8 Å2 for LDTI
atoms per Ångström from a point approximately 5 Å from
the Cα atom of Ser195 of trypsin (i.e. within the binding
loop of LDTI), indicating a rocking of LDTI with an
amplitude of about 3° around this point.
One unusual feature of the trypsin structure is that
Asn115 seems to be in the D-configuration instead of the
usual L-configuration (Figure 2). Various alternative
interpretations using L-asparagine (on the L-side of the
Cα atom, pulling the sidechain over to the D-side,
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Table 2
Final refinement statistics for the trypsin–LDTI complex
structure.
Resolution (Å) 6.0–2.03
Number of reflections (working/free) 15 443/963
σ cut-off None
R factor (working) 0.171
R factor (free) 0.228
Rmsd bond lengths (Å) 0.010
Rmsd bond angles (°) 1.978
Rmsd improper angles (°) 1.481
φ,ψ angle distribution*
in core region 193 (89.4)
in additionally allowed region 23 (10.6)
in generously allowed region 0 (0.0)
in disallowed region 0 (0.0)
Number of atoms
in structure 2063
in trypsin 1642
in LDTI 282
solvent 138
other (calcium ion in trypsin) 1 
*As defined by PROCHECK [41]; the percentage distribution is given
in parentheses.
Figure 1
Plot of the temperature factors of the Cα atoms of LDTI versus the
distance from the Cα atom of Ser195 of trypsin in the trypsin–LDTI
complex structure. There is a linear correlation of +0.95 between these
parameters.
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flipping the adjacent peptide bonds, etcetera) all gave
extreme stereochemical distortions, disallowed φ,ψ
angles and/or unacceptably large features in difference
electron-density maps (5–6σ peaks). On the other hand,
for the D-configuration, all crystallographic and stereo-
chemical parameters (except for the Cα chirality) are
acceptable and the Fo–Fc difference map is relatively fea-
tureless. Asn115 is one of three asparagine residues in
bovine pancreatic trypsin known to undergo spontaneous
deamidation [22]. The sequence around Asn115 in
porcine pancreatic trypsin is identical to that of the
bovine enzyme, with the exception of a Thr→Ser change
at position 113. Spontaneous deamidation of asparagine
residues at pH > 5 is believed to occur via an intermedi-
ate succinimide formed by nucleophilic attack of the
peptide nitrogen atom of the next residue followed by
loss of ammonia [23]. The five-membered succinimide
ring undergoes hydrolysis and racemization to give
L-isoaspartic acid, D-isoaspartic acid, L-aspartic acid or
D-aspartic acid. The respective ratios of these products
from the model hexapeptide Val-Tyr-Pro-Asn-Gly-Ala is
8:3:2:1 [24]. The electron density around residue 115 is
clear enough to distinguish between isoaspartic acid and
aspartic acid, but not between aspartic acid and
asparagine (Figure 2). The environment of the sidechain
would argue for aspartic acid, as the two end atoms are
within hydrogen-bonding distance (< 3.0 Å) of two hydro-
gen-bond donors in one case (Gly148 N and Ser147 N)
and one hydrogen-bond donor (Ser146 N) and two atoms
capable of donating or accepting a hydrogen atom
(Ser146 Oγ and a solvent molecule) in the second case. It
is interesting to note that these contacting residues are
from a symmetry-related molecule, giving rise to the
intriguing hypothesis, that only upon deamidation/racem-
ization of L-Asn115 to D-Asp can these crystals form,
explaining why crystals first appeared two years after
setting up the experiments. A new X-PLOR dictionary
(‘ASD’) for D-asparagine and later D-aspartic acid was
created and the residue refined as such.
Description of the structure
LDTI has a fold very similar to the third domain of the
turkey ovomucoid inhibitor (OVO3; PDB accession code
1PPF) [21]. The Cα positions of the two inhibitors for
residues 5–30 and 35–40 (15–40 and 51–56 in OVO3)
have an rms difference of 0.79 Å (Figure 3). The loops
connecting these parts of the two inhibitors are, however,
quite different: in LDTI there is a short, direct connec-
tion, whereas in OVO3 there is an extra turn in the central
α helix and a rather long stretch of random-coil structure.
The N terminus of LDTI, besides being ten residues
shorter than in OVO3, remains closer to the central α
helix due to a second disulfide bond between residues 4
and 29. The structure of LDTI is more comparable to the
insect serine proteinase inhibitor rhodniin, whose struc-
ture in complex with thrombin has been solved [25]
(PDB accession code 1TBR). Superposition of the Cα
atoms of LDTI and rhodniin gives an rms difference of
0.58 Å and 0.51 Å against the first domain (36 Cα pairs)
and the second domain (35 Cα pairs), respectively. This
is not much higher than the Cα rms difference observed
between the two domains of rhodniin themselves (0.45 Å;
35 Cα pairs). Like OVO3, rhodniin has an extra turn of
the central helix and inserted residues relative to LDTI,
but the following β strand of rhodniin aligns very closely
with that from LDTI.
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Figure 2
Stereoview of the electron density around
Asn115 of trypsin. The structure of Asn115,
interpreted and refined as an L-Asn is shown in
green, while its structure interpreted and
refined as a D-Asp residue is shown in
magenta. Part of a symmetry-related trypsin
molecule which makes potential hydrogen
bonds with D-Asp is shown in yellow. Two
solvent molecules occupy the other electron
density in each of the two interpretations. The
light blue electron density is from an Fo–Fc
difference Fourier (3σ cut-off) in which residues
113–117 and two adjacent water molecules
were left out of the Fc calculation. Also shown
is electron density (–4σ, red; +4σ, +5σ and
+6σ, purple) from an Fo–Fc difference Fourier
calculated from the L-Asn structure (green). The
4σ negative density at the Cβ position on the L
side of the Cα atom of residue 115, coupled
with the 6σ positive density on the D side,
indicates a D amino acid. Hydrogen bonds are
shown as red dashed lines and their distances
are given in Å.
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Structure
The structure of the trypsin molecule is virtually identi-
cal to that used as the trial structure except for a few
flexible, solvent-exposed sidechains (Arg62, Arg125,
Glu188, Gln221, and Lys222). The sidechain of Tyr217
is also different, having been pushed into another confor-
mation by the binding of LDTI. Other differences
include those around residues 60–61 and 145–146, which
were cleaved in the trial structure (β-trypsin) but which
are intact in our preparation, and two peptide bonds
(between residues 26–27 and 147–148) which have been
flipped in our structure. Residue Asn115 was interpreted
as having undergone deamidation and racemization to
D-aspartic acid as described above.
Interactions between LDTI and trypsin
As is usual for small protein inhibitors of serine pro-
teinases, LDTI interacts with trypsin primarily through
its binding loop (Figure 4). The substrate-specific
residue, Lys8, of LDTI extends into the S1 pocket
(notation of Berger and Schechter [26]) forming an ionic
interaction with Asp189 of trypsin. The Nζ atom of Lys8
also forms a hydrogen bond with the Oγ atom of Ser190
and water-mediated hydrogen bonds to the mainchain
oxygen atom of Val227, the Oγ atom of Ser190 and the
sidechain of Asp189. The mainchain atoms of residues
3–10 of LDTI form hydrogen bonds with mainchain
atoms of trypsin in a pseudo-antiparallel β-sheet fashion.
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Figure 3
Stereo Cα tracing of LDTI (green)
superimposed with the third domain of the
ovomucoid inhibitor from turkey (magenta;
PDB accession code 1PPF) [21]. The primary
specificity residues and disulfide bridges
(yellow) are also shown; the N and C termini
are labeled.
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Figure 4
Stereoview of the interactions between the
binding loop of LDTI (solid bonds) and the
active-site region of trypsin (open bonds). A
number of hydrogen bonds (dashed lines) are
formed between mainchain atoms in a
pseudo-antiparallel β-sheet fashion. The P1
specificity-determining residue of LDTI, Lys8,
forms an ionic interaction with Asp189 of
trypsin as well as other hydrogen bonds within
the S1 specificity pocket. Important solvent
molecules in the interaction interface are
shown as large red spheres. Atoms are shown
in standard colors.
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Besides Lys8, the sidechain atoms of Val3 (P6), Ala5
(P4), Pro7 (P2), Ile9 (P1′) and Leu10 (P2′)  make signifi-
cant van der Waals contacts with trypsin. Analysis of the
solvent-accessible surface of free LDTI and LDT1
bound to trypsin indicates an interaction area of ~725 Å2
with Lys8 contributing about 28% of this total (Figure 5).
The catalytic Oγ atom of Ser195 is poised to attack the
carbonyl carbon atom of Lys8 of LDTI, refining to only
2.8 Å away, although the electron density of this peptide
shows it still to be clearly planar with no evidence of
partial binding or distortion by the enzyme. The Tyr217
sidechain of trypsin has been pushed into a different
conformation by Val3 of LDTI which seems to form a
hydrogen bond with its carbonyl oxygen atom to the Oη
atom of the tyrosine sidechain. This is the only major
adaptation by trypsin to the binding of LDTI.
Modeling of tryptase
The model of the tryptase–LDTI complex is a reason-
able protein complex structure according to all criteria
examined by PROCHECK (i.e. mainchain and sidechain
conformational angles, ideal bond lengths and angles,
peptide and sidechain planarity, etcetera) as well as pos-
sessing good internal nonbonded and electrostatic con-
tacts. Stereochemical idealization in vacuo reduced the
energy of the system from +3785 to –6355 kcal/mol. The
model is similar to that constructed by Johnson and
Barton [20] with a few exceptions: the remodeling of the
long insertion loop between residues 174–175; loops
125–129, 184–187 and 202–206 (which were made to
follow chymotrypsin more closely as the sequence in
these loops is more chymotrypsin-like); and loops 23–25
and 35–41 which follow trypsin and chymotrypsin more
closely as there are no insertions/deletions in these areas
to suggest a different structure. Loop 144–147 was also
extended in a different manner (in a classic β-hairpin
structural motif) relative to chymotrypsin and trypsin as
this type of structural motif is frequently seen for inser-
tions in β turns between related proteins. The overall
rms difference between the Cα positions of the model of
Johnson and Barton and ours is 0.46 Å for 180 Cα pairs
(73% of the total).
Most of the overall observations made by Johnson and
Barton [20] on the model of the tryptase structure are
reinforced by our own model of the enzyme. The pI of
tryptase is estimated to be around 6.4 based on its amino
acid composition [27]. This is much lower than for trypsin
and chymotrypsin, which have pI’s around 9.0–9.5, and is
counterintuitive as the tryptase tetramer is believed to
bind and be stabilized by negatively charged proteogly-
cans [2,9,12]. As noted by Johnson and Barton [20], the
charge distribution on the surface of tryptase is very
uneven. The face of the molecule containing the active
site (the ‘front’ side) is quite negatively charged. In con-
trast, the ‘back’ side of the molecule has large hydropho-
bic patches, possibly involved in tetramer formation, and
a large positively charged patch, which may be the
heparin–proteoglycan interaction site (Figure 6). The
large number of histidine residues in tryptase (12) relative
to trypsin (four) and chymotrypsin (two), means that its
net charge changes dramatically in going from the mast
cell granule, where the pH has been measured to be 5.55
[28], to the extracellular space, where the pH is around
7.5. For tryptase this means a change of net charge from
~+7 to ~–5 upon degranulation, while trypsin and chy-
motrypsin would both have a net positive charge at these
pH levels (Figure 7).
Inhibition of tryptase
Our model and the interactions between LDTI and
trypsin seen in the crystal structure of the complex
support the assertion of Johnson and Barton [20] that the
insertion of nine residues after residue 174 in tryptase
(the 174 loop) would prevent binding of the two Kazal-
type trypsin inhibitors OVO3 and bovine pancreatic
trypsin inhibitor (BPTI). In OVO3, residues 8–14 of the
N terminus would clash with the insertion. In LDTI,
besides being ten residues shorter, the N terminus is held
away from the tryptase 174 loop by the disulfide bond
between residues 4 and 29. In BPTI, the proline at posi-
tion 13 and the disulfide bond between residues 5 and 55
would also keep the N-terminal loop away from the 174
loop of tryptase, but residues 36–42 would encounter
steric hindrance upon binding. In the LDTI–tryptase
complex, the N-terminal loop is held near the LDTI
binding loop by the disulfide bond between residue 14 of
the binding loop and residue 38 of tryptase. The insertion
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Figure 5
The solvent accessible surface area [42] of LDTI buried upon binding
to trypsin. LDTI interacts with trypsin almost exclusively through its
binding loop, residues 3–11. Mainchain interactions account for about
25% of the buried solvent-accessible surface. Residues 22 and 26 are
in the central helix of LDTI and both make van der Waals interactions
with the trypsin sidechain Gln192.
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after residue 174 would also explain the inability of the
Kunitz-type erythrina trypsin inhibitor (ETI), whose
uncomplexed structure has been solved [29], to inhibit
tryptase. Although ETI is from a different inhibitor
family, structural alignment based solely on the binding
loop (residues 61–66) gives an rms deviation of Cα posi-
tions of 0.52 Å with the corresponding residues of LDTI
(6–11). As aligned, the 174 loop of tryptase would cause
steric clashes with loops 111–115 and 70–74 of ETI. Our
modeling and structure comparisons do not show any
evidence that the insertion after residue 36 in tryptase,
on the other side of the active site from the 174 loop, has
any influence on substrate/inhibitor specificity as pro-
posed by Johnson and Barton [20]. Of the 19 residues of
trypsin that are within 4 Å of any atom of LDTI in the
complex structure, 17 are identical in tryptase (89%).
The two changes are Tyr217 and Tyr151 of trypsin.
Tyr217, whose Oη atom forms a hydrogen bond with the
mainchain oxygen atom of Val3 (P6), is the only residue
in trypsin to undergo a major sidechain reorientation
upon binding of LDTI. In tryptase, residue 217 is a glu-
tamic acid, which is incapable of forming the hydrogen
bond found in the LDTI–trypsin complex. In trypsin,
the phenolic ring of Tyr151 makes hydrophobic interac-
tions with the sidechain of Pro10 (P2′) of LDTI. In
tryptase, residue 151 is a leucine, also capable of forming
these hydrophobic interactions. The high degree of
sequence, and presumably structural, homology between
trypsin and tryptase around the binding loop of LDTI
imply that any difference in specificity between the two
enzymes is not due to any residues in this area. This
observation bolsters the proposition that the insertion in
tryptase after residue 174 is responsible for the higher
substrate selectivity of this proteinase as well as its resis-
tance to most trypsin inhibitors.
The lack of affinity of the serpins α1 proteinase inhibitor
antithrombin III towards tryptase cannot be inferred from
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Figure 6
Electrostatic potential surface representation of the model of tryptase.
(a) The region around the active site, including the binding loop of
LDTI. (b) The same view as (a) but rotated 180º. The sidechains of the
specificity residues P4 to P3′ of LDTI are labeled (nomenclature of
Berger and Schechter [26]), although Ala5 (P4) is hidden under the
tryptase 174 insertion loop and Lys8 (P1) is buried in the S1
specificity pocket. The highly electronegative active-site area (red)
corresponds well to the positively charged LDTI molecule (pI > 10).
The concentrated positively charged region (blue) in tryptase, shown at
the bottom of (b), could be responsible for heparin binding. (The figure
was made with the program GRASP [43].)
Figure 7
Theoretical charge titration curve of tryptase based on its amino acid
composition. Twelve histidine residues are responsible for the large
charge change between pH 5.5 (pH in the mast cell granules) and
pH 7.5 (pH of the extracellular medium).
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the differences between tryptase and trypsin, as no atomic
resolution structures of these molecules with their cognate
enzymes are known. Recent experiments employing fluo-
rescence energy transfer [30,31], however, have given rise
to a plausible mechanism to explain the large structural
rearrangement that these proteinase inhibitors undergo
subsequent to cleavage [32,33].
Binding of LDTI to tryptase
Most of the interactions LDTI makes with trypsin are
through its atoms in the binding loop (residues 3–10). In
particular, a pseudo-antiparallel β sheet is formed
between the mainchain atoms of LDTI and trypsin and
interactions occur with the sidechain of the P1 residue
Lys8. These interactions are certainly maintained in the
LDTI–tryptase complex (Figure 8). Of greater interest
are those interactions affected by changes in the
sequence of tryptase relative to trypsin. Trypsin has only
one extra hydrogen bond to LDTI, that is not found in
the tryptase model. This bond is between Val3 O of
LDTI and the sidechain of Tyr217 (Glu217 in tryptase),
which is also the only sidechain in trypsin to undergo a
significant conformational change upon binding of
LDTI. Tryptase, on the other hand, appears to be able
to form three more salt bridges and one extra hydrogen
bond with LDTI, relative to trypsin. Two of these salt
bridges are formed between the two N-terminal lysine
residues of LDTI and Asp147 (Ser147 in trypsin) and
Glu147A (an insertion in tryptase not present in trypsin).
In the 174 insertion loop of tryptase a third salt bridge,
between Asp174F and Arg28 of LDTI, and a hydrogen
bond between Thr174D and Cys29N of LDTI have also
been modeled, although one must remember that the
conformation of the 174 insertion loop is speculative.
Biological implications
Human tryptase is released into the extracellular
matrix in an active form during mast cell degranula-
tion. There are no known inhibitors of tryptase in
human plasma or in the extracellular space. The
enzyme has been implicated in a variety of mast cell
related disorders characterized by increased mast cell
numbers and excessive tryptase levels. Putative biologi-
cal functions include cleavage of neuropeptides (e.g.
vasoactive intestinal peptide, peptide histidine-methion-
ine and calcitonin gene related peptide), activation of
stromelysin and collagenase IV as well as fibronectin
and a strong cell-specific mitogenic effect. These and
other tryptase functions may account for some of the
pathogenic states observed in mast cell linked diseases.
Suitable inhibitors of tryptase, or antagonists of specific
tryptase functions, are indispensable in evaluating the
concept of tryptase inhibition and may prove to be
powerful therapeutic tools.
Leech-derived tryptase inhibitor (LDTI) represents the
first specific inhibitor of human tryptase and thus offers
a unique opportunity to evaluate the concept of tryptase
inhibition. LDTI may prove useful both as a therapeutic
protein and as a lead compound for the identification of
other tryptase inhibitors in targeted design efforts.
The crystal structure of trypsin in complex with LDTI
and the subsequent model of the tryptase–LDTI complex
reveal that LDTI interacts with serine proteinases pri-
marily through a binding loop composed of residues
3–10. In comparison to other trypsin inhibitors, LDTI
exhibits a shortened N terminus which is positioned in
close proximity to the central α helix. These features
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Figure 8
Stereoview representation of the model of the
tryptase (red)–LDTI (green) complex. The
large insertion loop after residue 174, relative
to trypsin and chymotrypsin, is shown in
purple and hangs down over LDTI. As
proposed by Johnson and Barton [20], this
loop is probably responsible for the relatively
high specificity of tryptase and its resistance
to other serine proteinase inhibitors. (The
figure was made using the program
MOLSCRIPT [44].)
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help to explain why LDTI, and not related inhibitors,
can bind and inhibit tryptase, which has a nine residue
insertion after residue 174 which hangs down over part
of the substrate-binding pocket. The presence of this
insertion makes tryptase far more selective than trypsin
in substrate specificity as well as making it resistant to
most trypsin inhibitors.
Materials and methods
Crystallization
Recombinant LDTI was expressed in S. cerevisiae and purified as
described [15]. Lyophilized recombinant LDTI in salt form (trifluoroac-
etate salt) was dissolved in 20 mM Tris-HCl, pH 8.0 to a final protein
concentration of 2.11 × 10–3 M. Lyophilized porcine pancreatic trypsin
(SIGMA, type IX, T–0134) to a final protein concentration of
1.05 × 10–3 M, was then dissolved in the same solution. The freshly pre-
pared LDTI–trypsin solution was centrifuged at 10 000 x g for 15 min
and filtered with 0.2 µm filters. Aliquots of the protein solution were then
immediately used for crystallization experiments. Crystals were grown
using the ‘hanging drop’ method at room temperature [34]. The crystal-
lization screening employed methods such as the sparse-matrix method
of trial conditions, which is biased and selected towards known crystal-
lization conditions for macromolecules (Hampton Research kits).
Data collection
A first X-ray diffraction data set from a form I crystal was collected at
room temperature using monochromatic synchrotron radiation
(λ = 0.95 Å) at the BW7A beamline of the EMBL outstation at DESY
(Hamburg), with a crystal-to-detector distance of 240 mm. A total of
130º of data were collected in steps of 1°/frame with an exposure
time of 30 000 counts/frame. An X-ray diffraction data set for crystal
form II was collected at room temperature using a 30 cm MAR
Research image plate detector system. Graphite-monochromatic CuKα
radiation was provided by an Enraf Nonius FR 591 rotating anode X-
ray generator operated at 45 kV and 100 mA. The crystal-to-detector
distance was set at 150 mm. Data were collected in steps of 1°/frame
for 100° with an exposure time of 900 s/frame. Both data sets were
processed with XDS [35].
Molecular replacement
Rotation and translation function calculations were carried out using
the program AMoRe [36] using the structure of porcine pancreatic
trypsin as determined by Huang et al. [37] (PDB accession code
1EPT). Assuming a crystal packing of 2.5 Å3/Da for crystal form II,
approximately 26.5 kDa of protein could be expected in the crystallo-
graphic asymmetric unit, implying the presence of one molecule of the
trypsin–LDTI complex (28.2 kDa). This was confirmed by the rotation
function results, using data from 15–3 Å and an integration radius of
25 Å, which gave a single clear solution. Translation functions were cal-
culated for both enantiomorphic space groups P41212 and P43212.
Rigid-body fitting with AMoRe was then carried out. Examination of the
structure was performed with the program O [38].
Refinement
The program X-PLOR [39] was used exclusively to refine the structure
of the trypsin–LDTI complex. After the second refinement cycle, a
Fo–Fc difference electron-density map was calculated to locate the
LDTI molecule. Using the structure of OVO3 [21] (accession code
1PPF) and that of glycosylated LDTI determined by NMR (W Stark,
personal communication) as guides, good electron density could be
recognized around the binding loop (residues 4–13) and the central
helix (residues 22–32). Further alternating cycles of refinement, exami-
nation of difference electron density maps and extension of the struc-
ture allowed placement of residues 2–41 of LDTI. Model building and
correction were carried out using the program O [38]. Only positive
peaks > 4σ in Fo–Fc difference electron-density maps with potential
hydrogen bonds were accepted as solvent sites.
Modeling of the tryptase–LDTI complex
A model of tryptase, based on bovine trypsin, has been constructed by
Johnson and Barton [20] and has been deposited in the Brookhaven
Protein Data Bank (accession code 1AAO). This and the structure of
the trypsin–LDTI complex formed the basis of our model of the
tryptase–LDTI complex. Although tryptase has the same primary prote-
olytic specificity as trypsin, in places it is sequentially more similar to
chymotrypsin, especially with respect to insertions and deletions.
Therefore, areas of tryptase that were more chymotrypsin-like in
sequence were modeled to be more chymotrypsin-like in structure.
Where neither trypsin nor chymotrypsin could be used as a guide for
sidechain conformations, selection was based on packing considera-
tions and likely sidechain rotamers for that amino acid as implemented
in the program O. In addition, peptide and sidechains were remodeled
if they were found to be in disallowed or rare conformations. The most
difficult modeling was for the nine amino acid insertion loop between
residues 174–175, which has no counterpart in either chymotrypsin or
trypsin. However, this loop folds down over LDTI (Figure 8) which
imposes considerable restrictions on possible conformations. Internal
water molecules that were found in both trypsin and chymotrypsin were
also included in the model. Water molecules were also placed in inter-
nal cavities found with the program VOIDOO [40], if the cavity was suf-
ficiently large and if potential hydrogen bonds to the protein were
present. The program PROCHECK [41] was used to check for unfa-
vorable mainchain and sidechain conformational angles. Energy mini-
mization was carried out with X-PLOR in vacuo, but with a
5 kcal/mol/Å–2 restraint on the Cα positions of tryptase and LDTI and
with formal sidechain charges turned off, although other partial charges
were left on. A total of 160 cycles of stereochemical idealization
without molecular dynamics were performed to relieve bad contacts
and other stereochemical strain in the model.
Accession numbers
The atomic coordinates of the LDTI–trypsin crystal structure and the
corresponding diffraction data have been deposited with the
Brookhaven Protein Data Bank with accession codes 1AN1 and
R1AN1SF, respectively.
Note added in proof
During the review of this manuscript, a paper has appeared which also
describes the structure of the LDTI–trypsin complex in the same crystal
form as described here and to a similar resolution (Stubbs, M., et al., &
Auerswald, E.A. (1997). J. Biol. Chem. 272, 19931–19937). The results
and conclusions of Stubbs et al. are very similar to those described
here. Although at the time they did not accept the possibility of a D-
amino acid for the unusual electron density around residue 115 in
trypsin, they agree that this interpretation is also consistent with their
electron density (M Stubbs, personal communication).
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